You are here

Cancer discovery DOI:10.1158/2159-8290.CD-13-0219

Connecting Genomic Alterations to Cancer Biology with Proteomics: The NCI Clinical Proteomic Tumor Analysis Consortium.

Publication TypeJournal Article
Year of Publication2013
AuthorsEllis, MJ, Gillette, M, Carr, SA, Paulovich, AG, Smith, RD, Rodland, KK, Townsend, RR, Kinsinger, C, Mesri, M, Rodriguez, H, Liebler, DC, Clinical Proteomic Tumor Analysis Consortium, (CPTAC)
JournalCancer discovery
Volume3
Issue10
Pages1108-12
Date Published2013/10/01
ISSN2159-8274
Abstract

Summary: The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods. Cancer Discov; 3(10); 1108-12. ©2013 AACR.

URLhttp://cancerdiscovery.aacrjournals.org/cgi/pmidlookup?view=long&pmid=24124232
DOI10.1158/2159-8290.CD-13-0219
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/24124232?dopt=Abstract